[Follow-up study of the development of autoantibodies in patients with chronic inflammatory bowel disease under anti-CD4 therapy].
7 of 22 patients with chronic inflammatory bowel diseases (Crohn's disease, ulcerative colitis) were treated with an anti-CD4-mAb. In the immunological monitoring the amounts of autoantibodies to pancreatic acini cells, to intestinal goblet cells, to granulocytes with perinuclear fluorescence pattern were examined and human anti-mouse-antibodies were measured. After anti-CD4 therapy the production of autoantibodies was widely unchanged. Therefore its use as parameter in the follow-up is restricted.